Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Influenza

Free Subscription Articles published in J Gen Virol Retrieve available abstracts of 46 articles: HTML format

Single Articles

September 2025
1. POKHAREL BR, Majumdar N, Williams F, Dickerson A, et al
   SARS-CoV-2 infection of substantia nigra pars compacta induces expression of miR-330-5p at 10 days post-infection.
   J Gen Virol. 2025;106.
   PubMed     Abstract available
   
   
   
2. BILLINGTON E, Di Genova C, Warren CJ, Thomas SS, et al
   Investigating factors driving shifts in subtype dominance within H5Nx clade 2.3.4.4b high pathogenicity avian influenza viruses.
   J Gen Virol. 2025;106:002150.
   PubMed     Abstract available
   
   
   
3. DI GENOVA C, Warren CJ, Johnson S, Riccio S, et al
   Pigeons exhibit low susceptibility and poor transmission capacity for H5N1 clade 2.3.4.4b high pathogenicity avian influenza virus.
   J Gen Virol. 2025;106.
   PubMed     Abstract available
   
   
   
4. PHAN N, Zaytseva Y, Lin CC, Mishra M, et al
   PUM2 binds SARS-CoV-2 RNA and PUM1 mildly reduces viral RNA levels, but neither protein affects progeny virus production.
   J Gen Virol. 2025;106:002152.
   PubMed     Abstract available
   
   
   
5. HA Y, Lee YH, Jo HS, Kwon TW, et al
   Susceptibility of different mouse strains to SARS-CoV-2 spike receptor-binding domain protein-induced lung inflammation: a comparative study.
   J Gen Virol. 2025;106.
   PubMed     Abstract available
   
   
   August 2025
6. BREITINGER U, Zakaria ZIS, Mahgoub HA, Wiessler AL, et al
   Activity and cellular distribution of ORF3a mutants of SARS-CoV-2 variants of concern.
   J Gen Virol. 2025;106:002135.
   PubMed     Abstract available
   
   
   July 2025
7. HIRST JC, Napier A, Burbidge D, Scott K, et al
   Glycan site loss in two egg-adapted live attenuated influenza vaccine strains does not cause antigenic mismatches.
   J Gen Virol. 2025;106.
   PubMed     Abstract available
   
   
   
8. YANG T, Zhu CY, Yu PH, Yang C, et al
   Arsenic trioxide could promote SARS-CoV-2 NSP12 protein degradation.
   J Gen Virol. 2025;106.
   PubMed     Abstract available
   
   
   
9. CHAN JCM, Ching RHH, Kock HHM, Long T, et al
   Evaluation of pandemic potential of the genotype 4 (G4) swine influenza virus using ex vivo and in vitro cultures of the human respiratory tract.
   J Gen Virol. 2025;106:002133.
   PubMed     Abstract available
   
   
   June 2025
10. CAPELASTEGUI F, Goldhill DH
    H5N1 2.3.4.4b: a review of mammalian adaptations and risk of pandemic emergence.
    J Gen Virol. 2025;106:002109.
    PubMed     Abstract available
    
    
    May 2025
11. AHMED MN, Abu Habib US, Abdallah AM, Emara MM, et al
    The impact of pre-existing immunity on the emergence of within-host immune-escape mutations in Omicron lineages.
    J Gen Virol. 2025;106:002108.
    PubMed     Abstract available
    
    
    April 2025
12. SANCHEZ-MARTINEZ A, Moore T, Freitas TS, Benzaken TR, et al
    Recent advances in the prevention and treatment of respiratory syncytial virus disease.
    J Gen Virol. 2025;106.
    PubMed     Abstract available
    
    
    
13. ARANDA AJ, Aguilar-Tipacamu G, Perez DR, Banuelos-Hernandez B, et al
    Emergence, migration and spreading of the high pathogenicity avian influenza virus H5NX of the Gs/Gd lineage into America.
    J Gen Virol. 2025;106:002081.
    PubMed     Abstract available
    
    
    March 2025
14. HANKINSON J, Young D, Wignall-Fleming EB, Lukoszek R, et al
    The Cap-proximal secondary structures of the 5'UTRs of parainfluenza virus 5 mRNAs specify differential sensitivity to type I interferon and IFIT1.
    J Gen Virol. 2025;106.
    PubMed     Abstract available
    
    
    February 2025
15. WEBB I, Erdmann M, Milligan R, Savage M, et al
    Examining the feasibility of replacing ORF3a with fluorescent genes to construct SARS-CoV-2 reporter viruses.
    J Gen Virol. 2025;106:002072.
    PubMed     Abstract available
    
    
    January 2025
16. RANDALL RE, Young D, Pisliakova M, Andrejeva J, et al
    Single-cycle parainfluenza virus type 5 vectors for producing recombinant proteins, including a humanized anti-V5 tag antibody.
    J Gen Virol. 2025;106.
    PubMed     Abstract available
    
    
    December 2024
17. KRISHNA B, Metaxaki M, Perera M, Wills M, et al
    Comparison of different T cell assays for the retrospective determination of SARS-CoV-2 infection.
    J Gen Virol. 2024;105.
    PubMed     Abstract available
    
    
    
18. ALNAJJAR S, Larios-Mora A, Van-Geelen A, Gallup J, et al
    Therapeutic efficacy of JNJ-49214698, an RSV fusion inhibitor, in RSV-infected neonatal lambs.
    J Gen Virol. 2024;105:002056.
    PubMed     Abstract available
    
    
    November 2024
19. BOE CA, Fiskebeck EMLZ, Reiten MR, Akerstedt J, et al
    Emergence of highly pathogenic avian influenza viruses H5N1 and H5N5 in white-tailed eagles, 2021-2023.
    J Gen Virol. 2024;105:002035.
    PubMed     Abstract available
    
    
    October 2024
20. SAENKHAM-HUNTSINGER P, Drelich AK, Huang P, Peng BH, et al
    BALB/c mice challenged with SARS-CoV-2 B.1.351 beta variant cause pathophysiological and neurological changes within the lungs and brains.
    J Gen Virol. 2024;105:002039.
    PubMed     Abstract available
    
    
    September 2024
21. SHIPLEY R, Seekings AH, Byrne AMP, Shukla S, et al
    SARS-CoV-2 infection and transmission via the skin to oro-nasal route with the production of bioaerosols in the ferret model.
    J Gen Virol. 2024;105:002022.
    PubMed     Abstract available
    
    
    July 2024
22. HAVERTY R, McCormack J, Evans C, Purves K, et al
    SARS-CoV-2 infects neurons, astrocytes, choroid plexus epithelial cells and pericytes of the human central nervous system in vitro.
    J Gen Virol. 2024;105.
    PubMed     Abstract available
    
    
    
23. JAMES J, Thomas SS, Seekings AH, Mahmood S, et al
    Evaluating the epizootic and zoonotic threat of an H7N9 low-pathogenicity avian influenza virus (LPAIV) variant associated with enhanced pathogenicity in turkeys.
    J Gen Virol. 2024;105.
    PubMed     Abstract available
    
    
    
24. KING J, Pohlmann A, Bange A, Horn E, et al
    Red knots in Europe: a dead end host species or a new niche for highly pathogenic avian influenza?
    J Gen Virol. 2024;105.
    PubMed     Abstract available
    
    
    June 2024
25. BORDES L, Gerhards NM, Peters S, van Oort S, et al
    H5N1 clade 2.3.4.4b avian influenza viruses replicate in differentiated bovine airway epithelial cells cultured at air-liquid interface.
    J Gen Virol. 2024;105.
    PubMed     Abstract available
    
    
    May 2024
26. AHRENS AK, Jonsson SR, Svansson V, Brugger B, et al
    Iceland: an underestimated hub for the spread of high-pathogenicity avian influenza viruses in the North Atlantic.
    J Gen Virol. 2024;105.
    PubMed     Abstract available
    
    
    
27. KARA Y, Kizil MC, Iseri Nepesov M, Kacmaz E, et al
    Assessing the change in the epidemiology of seasonal respiratory viruses with the onset of the COVID-19 pandemic.
    J Gen Virol. 2024;105.
    PubMed     Abstract available
    
    
    February 2024
28. HARDISTY G, Nicol MQ, Shaw DJ, Bennet ID, et al
    Latent gammaherpesvirus infection enhances type I IFN response and reduces virus spread in an influenza A virus co-infection model.
    J Gen Virol. 2024;105.
    PubMed     Abstract available
    
    
    January 2024
29. HAYES RS, Oraby AK, Camargo C, Marchant DJ, et al
    Mapping respiratory syncytial virus fusion protein interactions with the receptor IGF1R and the impact of alanine-scanning mutagenesis on viral infection.
    J Gen Virol. 2024;105.
    PubMed     Abstract available
    
    
    
30. SEEKINGS AH, Liang Y, Warren CJ, Hjulsager CK, et al
    Transmission dynamics and pathogenesis differ between pheasants and partridges infected with clade 2.3.4.4b H5N8 and H5N1 high-pathogenicity avian influenza viruses.
    J Gen Virol. 2024;105.
    PubMed     Abstract available
    
    
    
31. MCMILLAN CLD, Wijesundara DK, Choo JJY, Amarilla AA, et al
    Enhancement of cellular immunity following needle-free vaccination of mice with SARS-CoV-2 spike protein.
    J Gen Virol. 2024;105.
    PubMed     Abstract available
    
    
    December 2023
32. APAA T, Withers AJ, Mackenzie L, Staley C, et al
    Lack of detection of SARS-CoV-2 in British wildlife 2020-21 and first description of a stoat (Mustela erminea) Minacovirus.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    November 2023
33. RANDALL RE, Young DF, Hughes DJ, Goodbourn S, et al
    Persistent paramyxovirus infections: in co-infections the parainfluenza virus type 5 persistent phenotype is dominant over the lytic phenotype.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    
34. GRAND RJ
    SARS-CoV-2 and the DNA damage response.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    October 2023
35. PHILIP AA, Hu S, Dai J, Patton JT, et al
    Recombinant rotavirus expressing the glycosylated S1 protein of SARS-CoV-2.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    
36. UCHECHUKWU CF, Anyaduba UL, Udekwu CC, Orababa OQ, et al
    Desmoglein-2 and COVID-19 complications: insights into its role as a biomarker, pathogenesis and clinical implications.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    
37. JUCKEL D, Desmarets L, Danneels A, Rouille Y, et al
    MERS-CoV and SARS-CoV-2 membrane proteins are modified with polylactosamine chains.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    July 2023
38. THURSZ M, Sadiq F, Tree JA, Karayiannis P, et al
    Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    June 2023
39. OKUYA K, Khalil AM, Esaki M, Nishi N, et al
    Newly emerged genotypes of highly pathogenic H5N8 avian influenza viruses in Kagoshima prefecture, Japan during winter 2020/21.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    
40. MIRABELLI C, Bragazzi Cunha J, Wotring JW, Sherman EJ, et al
    ARF6 is a host factor for SARS-CoV-2 infection in vitro.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    
41. APAA T, Withers AJ, Staley C, Blanchard A, et al
    Sarbecoviruses of British horseshoe bats; sequence variation and epidemiology.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    May 2023
42. JAMES J, Billington E, Warren CJ, De Sliva D, et al
    Clade 2.3.4.4b H5N1 high pathogenicity avian influenza virus (HPAIV) from the 2021/22 epizootic is highly duck adapted and poorly adapted to chickens.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    
43. DE BUHR H, de Leeuw OS, Harders F, Peeters BP, et al
    Emergence of biased hypermutation in a heterologous additional transcription unit in recombinant lentogenic Newcastle disease virus.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    
44. SULLIVAN DJ, Franchini M, Senefeld JW, Joyner MJ, et al
    Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    April 2023
45. SKOG E, Nykvist M, Naguib MM, Wille M, et al
    An oseltamivir-resistant avian H1N1 influenza A virus can transmit from mallards to chickens similarly to a wild-type strain: implications for the risk of resistance transmission to humans.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    
46. WOO PCY, de Groot RJ, Haagmans B, Lau SKP, et al
    ICTV Virus Taxonomy Profile: Coronaviridae 2023.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.